Registre français de la mucoviscidose ? Bilan des données, 2010. ,
Cystic fibrosis, The Lancet, vol.373, issue.9678, pp.1891-904, 2009. ,
DOI : 10.1016/S0140-6736(09)60327-5
Antibiotic Pharmacokinetics in Cystic Fibrosis, Clinical Pharmacokinetics, vol.13, issue.4, pp.228-53, 1987. ,
DOI : 10.2165/00003088-198713040-00002
Drug Disposition in Cystic Fibrosis, Clinical Pharmacokinetics, vol.35, issue.4, pp.313-342, 1998. ,
DOI : 10.2165/00003088-199835040-00004
Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis, Pharmacy World and Science, vol.20, issue.4, pp.149-60, 1998. ,
DOI : 10.1023/A:1008634911114
Cefepime pharmacokinetics in cystic fibrosis, Pharmacotherapy, vol.13, issue.5, pp.465-70, 1993. ,
Ceftazidime disposition in acute and stable cystic fibrosis, Clinical Pharmacology and Therapeutics, vol.36, issue.3, pp.355-62, 1984. ,
DOI : 10.1038/clpt.1984.187
Cloxacillin absorption and disposition in cystic fibrosis, The Journal of Pediatrics, vol.105, issue.5, pp.829-864, 1984. ,
DOI : 10.1016/S0022-3476(84)80317-0
Pharmacokinetics of Meropenem in Patients with Cystic Fibrosis, European Journal of Clinical Microbiology & Infectious Diseases, vol.17, issue.12, pp.873-879, 1998. ,
DOI : 10.1007/s100960050211
Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Beta-lactam antibiotics, Chest, vol.94, issue.2, pp.115-120, 1988. ,
DOI : 10.1378/chest.94.2.115S
Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics, Chest, vol.94, issue.2, 1988. ,
DOI : 10.1378/chest.94.2.120S
Pharmacokinetics of tobramycin in cystic fibrosis, The Journal of Pediatrics, vol.100, issue.2, pp.318-339, 1982. ,
DOI : 10.1016/S0022-3476(82)80664-1
Population Pharmacokinetics of Aminoglycoside Antibiotics in Patients With Cystic Fibrosis, Therapeutic Drug Monitoring, vol.21, issue.3, pp.281-289, 1999. ,
DOI : 10.1097/00007691-199906000-00004
Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis, Clin Pharm, vol.2, issue.3, pp.262-266, 1983. ,
L'antibioth??rapie dans la mucoviscidose. I. Particularit??s pharmacologiques des antibiotiques, Archives de P??diatrie, vol.7, issue.5, pp.519-547, 2000. ,
DOI : 10.1016/S0929-693X(00)89009-0
Accréditation et d'Évaluation en Santé, Société française de pédiatrie. Conférence de consensus -Prise en charge du patient atteint de mucoviscidose -Pneumologie et infectiologie, 2002. ,
Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis, American Journal of Health-System Pharmacy, vol.68, issue.4, pp.319-341, 2011. ,
DOI : 10.2146/ajhp100100
International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update???A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.25, issue.7, pp.745-55, 2006. ,
DOI : 10.1016/j.healun.2006.03.011
Quand le pneumologue doit-il envisager la greffe pulmonaire pour un de ses patients???, Revue des Maladies Respiratoires, vol.26, issue.4, pp.423-435, 2009. ,
DOI : 10.1016/S0761-8425(09)74047-1
R??sultats de la transplantation pulmonaire, Revue des Maladies Respiratoires, vol.27, issue.8, pp.921-959, 2010. ,
DOI : 10.1016/j.rmr.2010.08.001
Tobramycin Pharmacokinetics in Patients with Cystic Fibrosis Preceding and Following Lung Transplantation, Therapeutic Drug Monitoring, vol.21, issue.2, pp.161-166, 1999. ,
DOI : 10.1097/00007691-199904000-00004
Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation, Transplant Infectious Disease, vol.123, issue.6, pp.616-637, 2011. ,
DOI : 10.1111/j.1399-3062.2011.00651.x
Mise au point sur le bon usage des aminosides administrés par voie injectable : gentamicine, tobramycine, netilmicine, amikacine, 2011. ,
Niveau de preuve pour le suivi th??rapeutique pharmacologique de la vancomycine, Th??rapie, vol.66, issue.1, pp.29-37, 2011. ,
DOI : 10.2515/therapie/2011005
Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health???System Pharmacists, and the Society of Infectious Diseases Pharmacists, Clinical Infectious Diseases, vol.49, issue.3, pp.325-332, 2009. ,
DOI : 10.1086/600877
Niveau de preuve du suivi th??rapeutique pharmacologique de la teicoplanine, Th??rapie, vol.66, issue.1, pp.45-50, 2011. ,
DOI : 10.2515/therapie/2011003
Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, vol.46, issue.2, pp.201-212, 2008. ,
DOI : 10.1086/524669
Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications, Antimicrobial Agents and Chemotherapy, vol.53, issue.1, pp.24-34, 2009. ,
DOI : 10.1128/AAC.00705-08
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612175
What is the best method for measuring renal function in adults and children with cystic fibrosis?, Journal of Cystic Fibrosis, vol.9, issue.2, pp.124-133, 2010. ,
DOI : 10.1016/j.jcf.2009.12.002
Cr-EDTA Measured Renal Function During the First Weeks Following Lung Transplantation, American Journal of Transplantation, vol.269, issue.4 Pt 2, pp.1420-1426, 2009. ,
DOI : 10.1111/j.1600-6143.2009.02627.x
Progressive Chronic Kidney Disease After Pediatric Lung Transplantation, American Journal of Transplantation, vol.48, issue.7, pp.1739-1786, 2005. ,
DOI : 10.1093/ndt/16.8.1681
Mechanisms of the rapid decline in glomerular filtration rate following lung transplantation in patients with cystic fibrosis, Am. J. Transplant, vol.10, issue.4, pp.954-955, 2010. ,
Chronic Calcineurin Inhibitor Nephrotoxicity: Reflections on an Evolving Paradigm, Clinical Journal of the American Society of Nephrology, vol.4, issue.12, pp.2029-2063, 2009. ,
DOI : 10.2215/CJN.03820609
Calcineurin Inhibitor Nephrotoxicity, Clinical Journal of the American Society of Nephrology, vol.4, issue.2, pp.481-508, 2009. ,
DOI : 10.2215/CJN.04800908
URL : http://cjasn.asnjournals.org/content/4/2/481.full.pdf
Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: The significance of baseline glomerular filtration rate, The Journal of Heart and Lung Transplantation, vol.31, issue.3, pp.259-65, 2012. ,
DOI : 10.1016/j.healun.2011.12.010
Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial, Transplantation, vol.89, issue.7, pp.864-72, 2010. ,
DOI : 10.1097/TP.0b013e3181cbac2d
Dramatic Improvement in Survival After Lung Transplantation Over Time: A Single Center Experience, Transplantation Proceedings, vol.41, issue.2, pp.687-91, 2009. ,
DOI : 10.1016/j.transproceed.2008.12.016
URL : https://hal.archives-ouvertes.fr/inserm-00387548
Registre français de la mucoviscidose ? Bilan des données, 2010. ,
Malnutrition in adults with cystic fibrosis, European Journal of Clinical Nutrition, vol.59, issue.1, pp.152-156, 2005. ,
DOI : 10.1038/sj.ejcn.1602039
Lung transplantation and life extension in children with cystic fibrosis, The Lancet, vol.354, issue.9190, pp.1591-1594, 1999. ,
DOI : 10.1016/S0140-6736(99)03031-7
Improved results of lung transplantation for patients with cystic fibrosis, The Journal of Thoracic and Cardiovascular Surgery, vol.109, issue.2, pp.224-234, 1995. ,
DOI : 10.1016/S0022-5223(95)70383-7
Aspergillus infection in lung transplant patients: incidence and prognosis, European Journal of Clinical Microbiology & Infectious Diseases, vol.7, issue.1, pp.879-86, 2007. ,
DOI : 10.1007/s10096-007-0376-3
Posttransplant Lymphoproliferative Disease after Lung Transplantation, Clinical and Developmental Immunology, vol.12, issue.4, p.430209, 2013. ,
DOI : 10.1182/blood-2010-03-274076
URL : http://doi.org/10.1155/2013/430209
Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis, Pharmacy World and Science, vol.20, issue.4, pp.149-60, 1998. ,
DOI : 10.1023/A:1008634911114
Antibiotic Pharmacokinetics in Cystic Fibrosis, Clinical Pharmacokinetics, vol.13, issue.4, pp.228-53, 1987. ,
DOI : 10.2165/00003088-198713040-00002
Accréditation et d'Évaluation en Santé, Société française de pédiatrie. Conférence de consensus -Prise en charge du patient atteint de mucoviscidose -Pneumologie et infectiologie, 2002. ,
Cystic fibrosis, The Lancet, vol.373, issue.9678, pp.1891-904, 2009. ,
DOI : 10.1016/S0140-6736(09)60327-5
Mucoviscidose??: physiopathologie, g??n??tique, aspects cliniques et th??rapeutiques, EMC - P??diatrie - Maladies infectieuses, vol.1, issue.1, pp.60-70, 2002. ,
DOI : 10.1016/S1637-5017(06)74491-X
WHAT IS A CYSTIC FIBROSIS DIAGNOSIS?, Clinics in Chest Medicine, vol.19, issue.3, pp.589-95, 1998. ,
DOI : 10.1016/S0272-5231(05)70091-5
Cystic fibrosis: terminology and diagnostic algorithms, Thorax, vol.61, issue.7, pp.627-662, 2006. ,
DOI : 10.1136/thx.2005.043539
DRIED-BLOOD SPOT SCREENING FOR CYSTIC FIBROSIS IN THE NEWBORN, The Lancet, vol.313, issue.8114, pp.472-476, 1979. ,
DOI : 10.1016/S0140-6736(79)90825-0
Genotype Analysis and Phenotypic Manifestations of Children With Intermediate Sweat Chloride Test Results, Chest, vol.118, issue.6, pp.1591-1598, 2000. ,
DOI : 10.1378/chest.118.6.1591
Le dépistage néonatal systématique de la mucoviscidose en France : état des lieux et persepectives après 5 ans de fonctionnement, 2009. ,
Génétique de la mucoviscidose, Médecine Thérapeutique pédiatrique, vol.8, issue.3, pp.126-160 ,
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis, Cell, vol.73, issue.7, pp.1251-1255, 1993. ,
DOI : 10.1016/0092-8674(93)90353-R
The path of discovery in understanding the biology of cystic fibrosis and approaches to therapy, Am. J. Gastroenterol, vol.89, pp.97-105, 1994. ,
Nonclassic cystic fibrosis: A clinical conundrum, Pediatric Pulmonology, vol.137, issue.1, pp.10-12, 2003. ,
DOI : 10.1002/ppul.10286
Registre français de la mucoviscidose ? Bilan des données, 2005. ,
Cystic fibrosis: Nutritional consequences and management, Best Practice & Research Clinical Gastroenterology, vol.20, issue.3, pp.531-577, 2006. ,
DOI : 10.1016/j.bpg.2005.11.006
Liver disease in adult patients with cystic fibrosis: A frequent and independent prognostic factor associated with death or lung transplantation, Journal of Hepatology, vol.55, issue.6, pp.1377-82, 2011. ,
DOI : 10.1016/j.jhep.2011.03.028
Clinical importance of cystic fibrosis-related diabetes, Journal of Cystic Fibrosis, vol.3, issue.4, pp.209-231, 2004. ,
DOI : 10.1016/j.jcf.2004.08.001
Bone Histomorphometry in Adult Patients With Cystic Fibrosis, Chest, vol.118, issue.2, pp.434-443, 2000. ,
DOI : 10.1378/chest.118.2.434
Mechanisms of Increased Gastroesophageal Reflux in Patients With Cystic Fibrosis, The American Journal of Gastroenterology, vol.91, issue.9, pp.1346-53, 2012. ,
DOI : 10.3109/00365528809090232
Fertility issues in cystic fibrosis, Paediatric Respiratory Reviews, vol.3, issue.3, pp.236-276, 2002. ,
DOI : 10.1016/S1526-0542(02)00184-7
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus, European Respiratory Journal, vol.16, issue.4, pp.749-67, 2000. ,
DOI : 10.1034/j.1399-3003.2000.16d30.x
Respiratory Microbiology of Patients With Cystic Fibrosis in the United States, 1995 to 2005, Chest, vol.136, issue.6, pp.1554-60, 1995. ,
DOI : 10.1378/chest.09-0132
The Effect of Chronic Infection With Aspergillus fumigatus on Lung Function and Hospitalization in Patients With Cystic Fibrosis, Chest, vol.137, issue.1, pp.171-177, 2010. ,
DOI : 10.1378/chest.09-1103
Effect of Allergic Bronchopulmonary Aspergillosis on Lung Function in Children with Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.174, issue.11, pp.1211-1231, 2006. ,
DOI : 10.1164/rccm.200603-423OC
General considerations for lung function testing, European Respiratory Journal, vol.26, issue.1, pp.153-61, 2005. ,
DOI : 10.1183/09031936.05.00034505
Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis, The Journal of Pediatrics, vol.151, issue.2, pp.134-139, 2007. ,
DOI : 10.1016/j.jpeds.2007.03.006
Predictors of mortality in adults with cystic fibrosis, Pediatric Pulmonology, vol.85, issue.6, pp.525-557, 2007. ,
DOI : 10.1002/ppul.20619
Le programme fran??ais de d??pistage n??onatal syst??matique dans la mucoviscidose??: r??sultats et interrogations sur un million de tests, Immuno-analyse & Biologie Sp??cialis??e, vol.20, issue.4, pp.228-261, 2005. ,
DOI : 10.1016/j.immbio.2005.05.001
Consulté le 19 février 2013 ,
Les bases mol??culaires de la mucoviscidose en France : plus de 300 mutations et 506 g??notypes diff??rents sont en cause., m??decine/sciences, vol.14, issue.12, pp.1413-1434, 1998. ,
DOI : 10.4267/10608/984
Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study, The Lancet, vol.361, issue.9370, pp.1671-1677, 2003. ,
DOI : 10.1016/S0140-6736(03)13368-5
Association Between Respiratory Tract Methicillin-Resistant S<emph type="ital">taphylococcus aureus</emph> and Survival in Cystic Fibrosis, JAMA, vol.303, issue.23, pp.2386-92, 2010. ,
DOI : 10.1001/jama.2010.791
Cystic Fibrosis Survival Rates, American Journal of Diseases of Children, vol.139, issue.7, pp.669-71, 19601985. ,
DOI : 10.1001/archpedi.1985.02140090031019
Cystic Fibrosis Pulmonary Guidelines, American Journal of Respiratory and Critical Care Medicine, vol.176, issue.10, pp.957-69, 2007. ,
DOI : 10.1164/rccm.200705-664OC
Systematic review of N-acetylcysteine in cystic fibrosis, Acta Paediatrica, vol.331, issue.Suppl 111, pp.38-41, 19921999. ,
DOI : 10.1111/j.1651-2227.1999.tb01265.x
A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis, The Journal of Pediatrics, vol.126, issue.4, pp.515-538, 1995. ,
DOI : 10.1016/S0022-3476(95)70343-8
Antibiotic prophylaxis in infants and young children with cystic fibrosis: A randomized controlled trial, The Journal of Pediatrics, vol.140, issue.3, pp.299-305, 2002. ,
DOI : 10.1067/mpd.2002.121930
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis, New England Journal of Medicine, vol.340, issue.1, pp.23-30, 1999. ,
DOI : 10.1056/NEJM199901073400104
lung infection, Journal of Antimicrobial Chemotherapy, vol.19, issue.6, pp.831-839, 1987. ,
DOI : 10.1093/jac/19.6.831
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis, European Respiratory Journal, vol.20, issue.3, pp.658-64, 2002. ,
DOI : 10.1183/09031936.02.00248102
Macrolide antibiotics as immunomodulatory medications: Proposed mechanisms of action, Pharmacology & Therapeutics, vol.117, issue.3, pp.393-405, 2008. ,
DOI : 10.1016/j.pharmthera.2007.11.001
Heterogeneity of Treatment Response to Azithromycin in Patients with Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.172, issue.8, pp.1008-1020, 2005. ,
DOI : 10.1164/rccm.200502-218OC
Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With <emph type="ital">Pseudomonas aeruginosa</emph><subtitle>A Randomized Controlled Trial</subtitle>, JAMA, vol.303, issue.17, pp.1707-1722, 2010. ,
DOI : 10.1001/jama.2010.563
Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis???State of the Art: Cystic Fibrosis Foundation Consensus Conference, Clinical Infectious Diseases, vol.37, issue.s3, pp.225-264, 2003. ,
DOI : 10.1086/376525
Successful treatment of methicillin-resistantStaphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis, Pediatric Pulmonology, vol.54, issue.3, pp.221-224, 2002. ,
DOI : 10.1002/ppul.10062
Utilisation du lin??zolide dans le traitement des infections broncho-pulmonaires du patient adulte atteint par la mucoviscidose, Revue de Pneumologie Clinique, vol.62, issue.6, pp.374-382, 2006. ,
DOI : 10.1016/S0761-8417(06)75470-0
Eradication of pulmonary methicillin-resistant staphylococcus aureus (MRSA) in cystic fibrosis with linezolid, Journal of Cystic Fibrosis, vol.3, issue.1, p.61, 2004. ,
DOI : 10.1016/j.jcf.2003.12.010
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.168, issue.8, pp.918-51, 2003. ,
DOI : 10.1164/rccm.200304-505SO
Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis???the TOPIC study: a randomised controlled trial, The Lancet, vol.365, issue.9459, pp.573-581, 2005. ,
DOI : 10.1016/S0140-6736(05)17906-9
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis, Cochrane Database Syst. Rev. Online, vol.2, p.2009, 2012. ,
Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring, European Journal of Pharmaceutical Sciences, vol.45, issue.1-2, pp.90-100, 2012. ,
DOI : 10.1016/j.ejps.2011.10.022
Home versus hospital intravenous antibiotic therapy for cystic fibrosis, Cochrane Database Syst. Rev. Online, vol.3, p.1917, 2012. ,
DOI : 10.1002/14651858.cd001917.pub3
Nutrition in patients with cystic fibrosis: a European Consensus, Journal of Cystic Fibrosis, vol.1, issue.2, pp.51-75, 2002. ,
DOI : 10.1016/S1569-1993(02)00032-2
Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis, Journal of Pediatric Gastroenterology and Nutrition, vol.35, issue.3, pp.246-59, 2002. ,
DOI : 10.1097/00005176-200209000-00004
Vitamin A supplementation for cystic fibrosis, Cochrane Database Syst. Rev. Online, vol.8, p.6751, 2012. ,
Vitamin D and bone health in adults with cystic fibrosis, Clinical Endocrinology, vol.163, issue.6 Suppl., pp.374-81, 2008. ,
DOI : 10.1111/j.1365-2265.2008.03216.x
Vitamin D supplementation for cystic fibrosis, Cochrane Database Syst. Rev. Online, vol.4, p.7298, 2012. ,
Infectious complications of lung transplantation. Impact of cystic fibrosis., American Journal of Respiratory and Critical Care Medicine, vol.149, issue.6, pp.1601-1608, 1994. ,
DOI : 10.1164/ajrccm.149.6.7516251
International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update???A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.25, issue.7, pp.745-55, 2006. ,
DOI : 10.1016/j.healun.2006.03.011
Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation?, Interactive CardioVascular and Thoracic Surgery, vol.13, issue.6, pp.631-635, 2011. ,
DOI : 10.1510/icvts.2011.271874
Pretransplant gastroesophageal reflux compromises early outcomes after lung transplantation, The Journal of Thoracic and Cardiovascular Surgery, vol.142, issue.1, pp.47-52, 2011. ,
DOI : 10.1016/j.jtcvs.2011.04.028
URL : http://dx.doi.org/10.1016/j.jtcvs.2011.04.028
Gastroesophageal reflux disease in lung transplant patients with cystic fibrosis, The American Journal of Surgery, vol.204, issue.5, pp.21-26, 2012. ,
DOI : 10.1016/j.amjsurg.2012.07.019
Techniques de transplantation bipulmonaires, Tech. Chir. -Thorax, pp.42-440, 2011. ,
INTERNATIONAL GUIDELINES FOR THE SELECTION OF LUNG TRANSPLANT CANDIDATES, Transplantation, vol.66, issue.7, pp.951-957, 1998. ,
DOI : 10.1097/00007890-199810150-00033
Lung transplantation for cystic fibrosis: a single center experience of 100 consecutive cases, European Journal of Cardio-Thoracic Surgery, vol.41, issue.2, pp.435-475, 2012. ,
DOI : 10.1016/j.ejcts.2011.06.017
The Registry of the International Society for Heart and Lung Transplantation: 29th Adult Lung and Heart-Lung Transplant Report???2012, The Journal of Heart and Lung Transplantation, vol.31, issue.10, pp.311073-86, 2012. ,
DOI : 10.1016/j.healun.2012.08.004
The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre, Journal of Hospital Infection, vol.56, issue.4, pp.277-82, 2004. ,
DOI : 10.1016/j.jhin.2004.01.003
Post-operative Infections in Cystic Fibrosis and Non???Cystic Fibrosis Patients After Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.26, issue.9, pp.890-897, 2007. ,
DOI : 10.1016/j.healun.2007.07.002
Survival of Lung Transplant Patients With Cystic Fibrosis Harboring Panresistant Bacteria Other Than Burkholderia cepacia, Compared With Patients Harboring Sensitive Bacteria, The Journal of Heart and Lung Transplantation, vol.26, issue.8, pp.834-842, 2007. ,
DOI : 10.1016/j.healun.2007.05.018
Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients, The Journal of Heart and Lung Transplantation, vol.21, issue.5, pp.547-54, 2002. ,
DOI : 10.1016/S1053-2498(01)00407-7
The Mechanism of Action of FK-506 and Cyclosporin A, Annals of the New York Academy of Sciences, vol.43, issue.1, pp.9-19, 1993. ,
DOI : 10.1111/j.1749-6632.1993.tb17137.x
Tacrolimus Versus Cyclosporine for Adult Lung Transplant Recipients: A Meta-Analysis, Transplantation Proceedings, vol.41, issue.5, pp.1821-1825, 2009. ,
DOI : 10.1016/j.transproceed.2008.11.016
Three-Year Results of a Randomized, Double-Blind, Controlled Trial of Mycophenolate Mofetil Versus Azathioprine in Cardiac Transplant Recipients, The Journal of Heart and Lung Transplantation, vol.24, issue.5, pp.517-542, 2005. ,
DOI : 10.1016/j.healun.2005.02.002
Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial, Transplantation, vol.89, issue.7, pp.864-72, 2010. ,
DOI : 10.1097/TP.0b013e3181cbac2d
Chronic Renal Failure after Transplantation of a Nonrenal Organ, New England Journal of Medicine, vol.349, issue.10, pp.931-971, 2003. ,
DOI : 10.1056/NEJMoa021744
Calcineurin Inhibitor Nephrotoxicity, Clinical Journal of the American Society of Nephrology, vol.4, issue.2, pp.481-508, 2009. ,
DOI : 10.2215/CJN.04800908
URL : http://cjasn.asnjournals.org/content/4/2/481.full.pdf
Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity, Clinical Transplantation, vol.6, issue.2, pp.1-15, 2008. ,
DOI : 10.1016/j.transproceed.2005.01.013
Remplacement des inhibiteurs de la calcineurine par des inhibiteurs du signal de prolif??ration apr??s transplantation r??nale : indications, r??sultats et inconv??nients, N??phrologie & Th??rapeutique, vol.5, issue.6, pp.395-399, 2009. ,
DOI : 10.1016/S1769-7255(09)73432-7
Pharmacokinetics of Drugs in Cystic Fibrosis, Clin. Rev. Allergy, vol.9, issue.1 2, pp.169-210, 1991. ,
DOI : 10.1007/978-1-4612-0475-6_11
Cloxacillin absorption and disposition in cystic fibrosis, The Journal of Pediatrics, vol.105, issue.5, pp.829-864, 1984. ,
DOI : 10.1016/S0022-3476(84)80317-0
Levofloxacin Pharmacokinetics in Adult Cystic Fibrosis, Chest, vol.131, issue.3, pp.796-802, 2007. ,
DOI : 10.1378/chest.06-1524
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075103
Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis, Antimicrobial Agents and Chemotherapy, vol.49, issue.12, pp.5013-5020, 2005. ,
DOI : 10.1128/AAC.49.12.5013-5017.2005
Ceftazidime disposition in acute and stable cystic fibrosis, Clinical Pharmacology and Therapeutics, vol.36, issue.3, pp.355-62, 1984. ,
DOI : 10.1038/clpt.1984.187
Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.54, issue.3, pp.1275-82, 2010. ,
DOI : 10.1128/AAC.00936-09
Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients., Antimicrobial Agents and Chemotherapy, vol.28, issue.6, pp.829-860, 1985. ,
DOI : 10.1128/AAC.28.6.829
Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics, Chest, vol.94, issue.2, 1988. ,
DOI : 10.1378/chest.94.2.120S
Population Pharmacokinetics of Aminoglycoside Antibiotics in Patients With Cystic Fibrosis, Therapeutic Drug Monitoring, vol.21, issue.3, pp.281-289, 1999. ,
DOI : 10.1097/00007691-199906000-00004
L'antibioth??rapie dans la mucoviscidose. I. Particularit??s pharmacologiques des antibiotiques, Archives de P??diatrie, vol.7, issue.5, pp.519-547, 2000. ,
DOI : 10.1016/S0929-693X(00)89009-0
Pharmacokinetics of amikacin in cystic fibrosis: A study of bronchial diffusion, European Journal of Clinical Pharmacology, vol.134, issue.suppl, pp.79-83, 1986. ,
DOI : 10.1007/BF00870991
Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.55, issue.6, pp.2927-2963, 2011. ,
DOI : 10.1128/AAC.01484-10
Cefepime pharmacokinetics in cystic fibrosis, Pharmacotherapy, vol.13, issue.5, pp.465-70, 1993. ,
Enhanced hepatic drug clearance in patients with cystic fibrosis, The Journal of Pediatrics, vol.117, issue.6, pp.972-981, 1990. ,
DOI : 10.1016/S0022-3476(05)80149-0
Pharmacokinetics of ticarcillin in patients with cystic fibrosis: A controlled prospective study, Clinical Pharmacology and Therapeutics, vol.47, issue.1, pp.73-81, 1990. ,
DOI : 10.1038/clpt.1990.11
Pharmacokinetics of Meropenem in Patients with Cystic Fibrosis, European Journal of Clinical Microbiology & Infectious Diseases, vol.17, issue.12, pp.873-879, 1998. ,
DOI : 10.1007/s100960050211
Increased Renal Clearance of Cefsulodin Due to Higher Glomerular Filtration Rate in Cystic Fibrosis, Clinical Pharmacokinetics, vol.18, issue.2, pp.168-75, 1990. ,
DOI : 10.2165/00003088-199018020-00006
Influence of the Glomerular Filtration Rate on Renal Clearance of Ceftazidime in Cystic Fibrosis, Clinical Pharmacokinetics, vol.15, issue.1, pp.57-65, 1988. ,
DOI : 10.2165/00003088-198815010-00005
Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers, Diagnostic Microbiology and Infectious Disease, vol.65, issue.2, pp.130-171, 2009. ,
DOI : 10.1016/j.diagmicrobio.2009.06.018
The Cystic Fibrosis Transmembrane Regulator (CFTR) in the kidney, Anais da Academia Brasileira de Ci??ncias, vol.72, issue.3, pp.399-406, 2000. ,
DOI : 10.1590/S0001-37652000000300013
Renal clearance of gentamicin in cystic fibrosis, The Journal of Pediatrics, vol.103, issue.6, pp.985-90, 1983. ,
DOI : 10.1016/S0022-3476(83)80737-9
Disposition of tobramycin in patients with cystic fibrosis: A prospective controlled study, The Journal of Pediatrics, vol.105, issue.1, pp.117-141, 1984. ,
DOI : 10.1016/S0022-3476(84)80375-3
Hepatic drug clearance in patients with mild cystic fibrosis*, Clinical Pharmacology & Therapeutics, vol.26, issue.5, pp.529-569, 1996. ,
DOI : 10.1016/S0009-9236(96)90181-2
Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis, Pharmacotherapy, vol.39, issue.1, pp.95-108, 2010. ,
DOI : 10.1097/00007691-199302000-00010
Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis, American Journal of Health-System Pharmacy, vol.68, issue.4, pp.319-341, 2011. ,
DOI : 10.2146/ajhp100100
Best practice in therapeutic drug monitoring, Br. J. Clin. Pharmacol, vol.52, issue.1, pp.5-10, 2001. ,
Suivi th??rapeutique pharmacologique pour l???adaptation de posologie des m??dicaments, Le Pharmacien Hospitalier, vol.43, issue.173, 2004. ,
DOI : 10.1016/S0768-9179(08)70010-5
Mise au point sur le bon usage des aminosides administrés par voie injectable : gentamicine, tobramycine, netilmicine, amikacine, 2011. ,
Niveau de preuve pour le suivi th??rapeutique pharmacologique de la vancomycine, Th??rapie, vol.66, issue.1, pp.29-37, 2011. ,
DOI : 10.2515/therapie/2011005
Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health???System Pharmacists, and the Society of Infectious Diseases Pharmacists, System Pharmacists, and the Society of Infectious Diseases Pharmacists, pp.325-332, 2009. ,
DOI : 10.1086/600877
Niveau de preuve du suivi th??rapeutique pharmacologique de la teicoplanine, Th??rapie, vol.66, issue.1, pp.45-50, 2011. ,
DOI : 10.2515/therapie/2011003
Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, vol.46, issue.2, pp.201-212, 2008. ,
DOI : 10.1086/524669
Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications, Antimicrobial Agents and Chemotherapy, vol.53, issue.1, pp.24-34, 2009. ,
DOI : 10.1128/AAC.00705-08
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612175
Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients, Transplant Infectious Disease, vol.11, issue.3, pp.211-220, 2009. ,
DOI : 10.1111/j.1399-3062.2009.00384.x
Evaluation of valganciclovir pharmacokinetics in lung transplant recipients, The Journal of Heart and Lung Transplantation, vol.31, issue.2, pp.159-66, 2012. ,
DOI : 10.1016/j.healun.2011.11.016
Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis, Journal of Antimicrobial Chemotherapy, vol.45, issue.4, pp.511-517, 2000. ,
DOI : 10.1093/jac/45.4.511
Tobramycin Pharmacokinetics in Patients with Cystic Fibrosis Preceding and Following Lung Transplantation, Therapeutic Drug Monitoring, vol.21, issue.2, pp.161-166, 1999. ,
DOI : 10.1097/00007691-199904000-00004
Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation, Transplant Infectious Disease, vol.123, issue.6, pp.616-637, 2011. ,
DOI : 10.1111/j.1399-3062.2011.00651.x
Aminoglycoside Nephrotoxicity, Current Drug Target -Infectious Disorders, vol.4, issue.2, pp.153-62, 2004. ,
DOI : 10.2174/1568005043340858
URL : https://hal.archives-ouvertes.fr/hal-00427524
Mechanisms of the rapid decline in glomerular filtration rate following lung transplantation in patients with cystic fibrosis, Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg, vol.10, issue.4, pp.954-955, 2010. ,
Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: The significance of baseline glomerular filtration rate, The Journal of Heart and Lung Transplantation, vol.31, issue.3, pp.259-65, 2012. ,
DOI : 10.1016/j.healun.2011.12.010
Introduction to Drug Pharmacokinetics in the Critically III Patient, Chest, vol.141, issue.5, pp.1327-1363, 2012. ,
DOI : 10.1378/chest.11-1396
Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation, Clinical Pharmacokinetics, vol.83, issue.2, pp.175-86, 2012. ,
DOI : 10.2165/11594760-000000000-00000
URL : https://hal.archives-ouvertes.fr/inserm-00925698
Bayesian Estimation of Mycophenolate Mofetil in Lung Transplantation, Using a Population Pharmacokinetic Model Developed in Kidney and Lung Transplant Recipients, Clinical Pharmacokinetics, vol.31, issue.3, pp.29-39, 2012. ,
DOI : 10.2165/11594050-000000000-00000
URL : https://hal.archives-ouvertes.fr/inserm-00639088
Cystic fibrosis, The Lancet, vol.373, issue.9678, pp.1891-904, 2009. ,
DOI : 10.1016/S0140-6736(09)60327-5
Accréditation et d'Évaluation en Santé, Société française de pédiatrie. Conférence de consensus -Prise en charge du patient atteint de mucoviscidose -Pneumologie et infectiologie, 2002. ,
Drug Disposition in Cystic Fibrosis, Clinical Pharmacokinetics, vol.35, issue.4, pp.313-342, 1998. ,
DOI : 10.2165/00003088-199835040-00004
Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis, Pharmacy World and Science, vol.20, issue.4, pp.149-60, 1998. ,
DOI : 10.1023/A:1008634911114
International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update???A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.25, issue.7, pp.745-55, 2006. ,
DOI : 10.1016/j.healun.2006.03.011
Lung transplantation and life extension in children with cystic fibrosis, The Lancet, vol.354, issue.9190, pp.1591-1594, 1999. ,
DOI : 10.1016/S0140-6736(99)03031-7
R??sultats de la transplantation pulmonaire, Revue des Maladies Respiratoires, vol.27, issue.8, pp.921-959, 2010. ,
DOI : 10.1016/j.rmr.2010.08.001
Tobramycin Pharmacokinetics in Patients with Cystic Fibrosis Preceding and Following Lung Transplantation, Therapeutic Drug Monitoring, vol.21, issue.2, pp.161-166, 1999. ,
DOI : 10.1097/00007691-199904000-00004
Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation, Transplant Infectious Disease, vol.123, issue.6, pp.616-637, 2011. ,
DOI : 10.1111/j.1399-3062.2011.00651.x
Registre français de la mucoviscidose ? Bilan des données, 2010. ,
Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis, Pediatric Pulmonology, vol.103, issue.5, pp.238-281, 1985. ,
DOI : 10.1002/ppul.1950010504
Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis, American Journal of Health-System Pharmacy, vol.68, issue.4, pp.319-341, 2011. ,
DOI : 10.2146/ajhp100100
Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis, Journal of Cystic Fibrosis, vol.10, issue.1, pp.25-30, 2011. ,
DOI : 10.1016/j.jcf.2010.09.003
Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis???the TOPIC study: a randomised controlled trial, The Lancet, vol.365, issue.9459, pp.573-581, 2005. ,
DOI : 10.1016/S0140-6736(05)17906-9
Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis, Pharmacotherapy, vol.39, issue.1, pp.95-108, 2010. ,
DOI : 10.1097/00007691-199302000-00010
Pharmacokinetics of Tobramycin in Adults with Cystic Fibrosis: Implications for Once-Daily Administration, Antimicrobial Agents and Chemotherapy, vol.44, issue.4, pp.809-822, 2000. ,
DOI : 10.1128/AAC.44.4.809-813.2000
L'antibioth??rapie dans la mucoviscidose. I. Particularit??s pharmacologiques des antibiotiques, Archives de P??diatrie, vol.7, issue.5, pp.519-547, 2000. ,
DOI : 10.1016/S0929-693X(00)89009-0
Antibiotic Pharmacokinetics in Cystic Fibrosis, Clinical Pharmacokinetics, vol.13, issue.4, pp.228-53, 1987. ,
DOI : 10.2165/00003088-198713040-00002
Clinical Pharmacology of Antibiotics and Other Drugs in Cystic Fibrosis, Drugs, vol.35, issue.5, pp.542-78, 1988. ,
DOI : 10.2165/00003495-198835050-00004
Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.55, issue.6, pp.2927-2963, 2011. ,
DOI : 10.1128/AAC.01484-10
Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers, Diagnostic Microbiology and Infectious Disease, vol.65, issue.2, pp.130-171, 2009. ,
DOI : 10.1016/j.diagmicrobio.2009.06.018
Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.54, issue.3, pp.1275-82, 2010. ,
DOI : 10.1128/AAC.00936-09
Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.51, issue.7, pp.2497-507, 2007. ,
DOI : 10.1128/AAC.01477-06
Pharmacokinetics of Meropenem in Patients with Cystic Fibrosis, European Journal of Clinical Microbiology & Infectious Diseases, vol.17, issue.12, pp.873-879, 1998. ,
DOI : 10.1007/s100960050211
Levofloxacin Pharmacokinetics in Adult Cystic Fibrosis, Chest, vol.131, issue.3, pp.796-802, 2007. ,
DOI : 10.1378/chest.06-1524
Linezolid Pharmacokinetics in Adult Patients with Cystic Fibrosis, Antimicrobial Agents and Chemotherapy, vol.48, issue.1, pp.281-285, 2004. ,
DOI : 10.1128/AAC.48.1.281-284.2004
Disposition of tobramycin in patients with cystic fibrosis: A prospective controlled study, The Journal of Pediatrics, vol.105, issue.1, pp.117-141, 1984. ,
DOI : 10.1016/S0022-3476(84)80375-3
Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients., Antimicrobial Agents and Chemotherapy, vol.28, issue.6, pp.829-860, 1985. ,
DOI : 10.1128/AAC.28.6.829
Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis, Clin Pharm, vol.2, issue.3, pp.262-266, 1983. ,
Individualizing gentamicin dosage in patients with cystic fibrosis: Limitations to pharmacokinetic approach, The Journal of Pediatrics, vol.110, issue.2, pp.303-313, 1987. ,
DOI : 10.1016/S0022-3476(87)80178-6
Dosing implications of altered gentamicin disposition in patients with cystic fibrosis, The Journal of Pediatrics, vol.100, issue.2, pp.312-320, 1982. ,
DOI : 10.1016/S0022-3476(82)80663-X
Pharmacokinetics of tobramycin in cystic fibrosis, The Journal of Pediatrics, vol.100, issue.2, pp.318-339, 1982. ,
DOI : 10.1016/S0022-3476(82)80664-1
Population Pharmacokinetics of Aminoglycoside Antibiotics in Patients With Cystic Fibrosis, Therapeutic Drug Monitoring, vol.21, issue.3, pp.281-289, 1999. ,
DOI : 10.1097/00007691-199906000-00004
Improved results of lung transplantation for patients with cystic fibrosis, The Journal of Thoracic and Cardiovascular Surgery, vol.109, issue.2, pp.224-234, 1995. ,
DOI : 10.1016/S0022-5223(95)70383-7
Lung transplantation for cystic fibrosis: a single center experience of 100 consecutive cases, European Journal of Cardio-Thoracic Surgery, vol.41, issue.2, pp.435-475, 2012. ,
DOI : 10.1016/j.ejcts.2011.06.017
Infectious complications of lung transplantation. Impact of cystic fibrosis., American Journal of Respiratory and Critical Care Medicine, vol.149, issue.6, pp.1601-1608, 1994. ,
DOI : 10.1164/ajrccm.149.6.7516251
Lung Transplantation for Cystic Fibrosis, Chest, vol.109, issue.3, pp.787-98, 1996. ,
DOI : 10.1378/chest.109.3.787
Prediction of Creatinine Clearance from Serum Creatinine, Nephron, vol.16, issue.1, pp.31-41, 1976. ,
DOI : 10.1159/000180580
What is the best method for measuring renal function in adults and children with cystic fibrosis?, Journal of Cystic Fibrosis, vol.9, issue.2, pp.124-133, 2010. ,
DOI : 10.1016/j.jcf.2009.12.002
Allergic bronchopulmonary aspergillosis disclosing mucoviscidosis], Rev Mal Respir, 2001. ,
Bayesian Estimation of Mycophenolate Mofetil in Lung Transplantation, Using a Population Pharmacokinetic Model Developed in Kidney and Lung Transplant Recipients, Clinical Pharmacokinetics, vol.31, issue.3 ,
DOI : 10.2165/11594050-000000000-00000
Dramatic Improvement in Survival After Lung Transplantation Over Time: A Single Center Experience, Transplantation Proceedings, vol.41, issue.2, pp.687-91, 2009. ,
DOI : 10.1016/j.transproceed.2008.12.016
URL : https://hal.archives-ouvertes.fr/inserm-00387548
Indications for lung and heart -lung transplantation in adults ,
Influence of Donor Characteristics on Outcome After Lung Transplantation: A Multicenter Study, The Journal of Heart and Lung Transplantation, vol.24, issue.9, pp.1347-53, 2005. ,
DOI : 10.1016/j.healun.2004.10.016
[Results of lung transplantation], Rev Mal Respir, 2010. ,